PepGen Inc.
pepgen.comWhat Do They Do?
Develops oligonucleotide therapies using its EDO delivery platform for patients with severe neuromuscular and neurologic diseases.
10-K for FY2025, filed Mar 4, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$17.8MView ↗
- ▼ −23% (Loss)
- vs −$23.1M in Q2 FY2025
A shift in disease focus
The older report described Duchenne muscular dystrophy as the lead program alongside myotonic dystrophy. The latest report focuses on myotonic dystrophy and says PepGen discontinued its Duchenne candidate and is winding down related research.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 4, 2026
Who Do They Compete With?
Competes with Avidity Biosciences, Dyne Therapeutics, Entrada Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Sarepta Therapeutics, ARTHEx Biotech, AMO Pharma, Sanofi, Astellas, Modalis, Kate Therapeutics, Arrakis Therapeutics, Rgenta Therapeutics, Alnylam Pharmaceuticals, Aro Biotherapeutics, Ionis Pharmaceuticals, and PYC Therapeutics
10-K for FY2025, filed Mar 4, 2026There are currently no approved therapies to treat the underlying cause of DM1. Product candidates currently in clinical development to…View ↗
Loading...
